1-(3,4-dimethoxy-phenyl)-propylamine; hydrochloride | 104174-57-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(3,4-dimethoxy-phenyl)-propylamine; hydrochloride
• 英文别名: [1-(3,4-Dimethoxyphenyl)propyl]amine hydrochloride；1-(3,4-dimethoxyphenyl)propan-1-amine;hydrochloride
• CAS: 104174-57-4
• 化学式: C₁₁H₁₇NO₂*ClH
• mdl: MFCD18483503
• 分子量: 231.722
• InChiKey: SEUUTSPOQSQOPW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.72
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  44.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-(3,4-dimethoxy-phenyl)-propylamine; hydrochloride 在 TEA 作用下， 以 N,N-二甲基甲酰胺 、 xylene 为溶剂， 反应 78.0h， 生成 methyl 2-[1-(3,4-dimethoxyphenyl)propyl-formylamino]acetate
  参考文献：
  名称：

  2-Mercaptoimidazoles, a new class of potent CCR2 antagonists

  摘要：

  We describe the synthesis and SAR of a new class of CCR2 antagonists based on a 2-mercaptoimidazole scaffold. The initial lead 1a was optimized to the 3,4-disubstituted analogues 1p-(S) and 1q-(S), which have IC50 values in the MCP-1 induced Ca-flux below 0.01 muM. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.064

文献信息

• Viral polymerase inhibitors
  申请人：Boehringer Ingelheim (Canada) Ltd.

  公开号：US20040224955A1

  公开（公告）日：2004-11-11

  A compound of the formula I: 1 wherein: X is CH or N; Y is O or S; Z is OH, NH 2 , NMeR 3 , NHR 3 ; OR 3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from O, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR 7 or CR 5 , wherein R 5 is H, halogen, or (C 1-6 ) alkyl and R 7 is H or (C 1-6 alkyl), with the proviso that X and A are not both N; R 6 is H, halogen, (C 1-6 alkyl) or OR 7 , wherein R 7 is H or (C 1-6 alkyl); R 1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C 1-3 )alkyl, (C 2-6 )alkenyl, phenyl(C 2-6 )alkenyl, (C 3-6 )cycloalkyl, (C 1-6 )alkyl, CF 3 , 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C 2-6 )alkenyl and phenyl(C 1-3 )alkyl), alkenyl, cycloalkyl, (C 1-6 )alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents; R 2 is selected from (C 1-6 )alkyl, (C 3-7 )cycloalkyl, (C 3-7 )cycloalkyl(C 1-3 )alkyl, (C 6-10 )bicycloalkyl, adamantyl, phenyl, and pyridyl, all of which is optionally substituted with from 1 to 4 substituents; R 3 is selected from H, (C 1-6 )alkyl, (C 3-6 )cycloalkyl, (C 3-6 )cycloalkyl(C 1-6 )alkyl, (C 6-10 )aryl, (C 6-10 )aryl(C 1-6 )alkyl, (C 2-6 )alkenyl, (C 3-6 )cycloalkyl(C 2-6 )alkenyl, (C 6-10 )aryl(C 2-6 )alkenyl, N{(C 1-6 ) alkyl} 2 , NHCOO(C 1-6 )alkyl(C 6-10 )aryl, NHCO(C 6-10 )aryl, (C 1-6 )alkyl-5- or 10-atom heterocycle, having 1 to 4 heteroatoms selected from O, N and S, and 5- or 10-atom heterocycle having 1 to 4 heteroatoms selected from O, N and S; wherein said alkyl, cycloalkyl, aryl, alkenyl and heterocycle are all optionally substituted with from 1 to 4 substituents; n is zero or 1; or a detectable derivative or salt thereof. The compounds of the invention may be used as inhibitors of hepatitis C virus replication. The invention further provides a method for treating or preventing hepatitis C virus infection.

  化合物的公式I:1，其中：X为CH或N; Y为O或S; Z为OH，NH2，NMeR3，NHR3; OR3或1至4个杂原子从O，N和S中选择的5-或6成员杂环，该杂环可选地用1至4个取代基取代; A为N，COR7或CR5，其中R5为H，卤素或（C1-6）烷基，R7为H或（C1-6）烷基，但X和A不同时为N; R6为H，卤素，（C1-6）烷基或OR7，其中R7为H或（C1-6）烷基; R1选自由O，N和S选择的1至4个杂原子的5-或6成员杂环，苯基，苯基（C1-3）烷基，（C2-6）烯基，苯基（C2-6）烯基，（C3-6）环烷基，（C1-6）烷基，CF3，1至4个杂原子从O，N和S中选择的9-或10成员杂环，其中所述的杂环，苯基，苯基（C2-6）烯基和苯基（C1-3）烷基，烯基，环烷基，（C1-6）烷基和杂原子环都可选地用1至4个取代基取代; R2选自（C1-6）烷基，（C3-7）环烷基，（C3-7）环烷基（C1-3）烷基，（C6-10）双环烷基，金刚烷基，苯基和吡啶基，所有这些都可选地用1至4个取代基取代; R3选自H，（C1-6）烷基，（C3-6）环烷基，（C3-6）环烷基（C1-6）烷基，（C6-10）芳基，（C6-10）芳基（C1-6）烷基，（C2-6）烯基，（C3-6）环烷基（C2-6）烯基，（C6-10）芳基（C2-6）烯基，N{（C1-6）烷基}2，NHCOO（C1-6）烷基（C6-10）芳基，NHCO（C6-10）芳基，（C1-6）烷基-1至4个杂原子从O，N和S中选择的5-或10成员杂环，其中所述的烷基，环烷基，芳基，烯基和杂环都可选地用1至4个取代基取代; n为零或1;或其可检测的衍生物或盐。该发明的化合物可用作丙型肝炎病毒复制的抑制剂。该发明还提供一种治疗或预防丙型肝炎病毒感染的方法。
• US6479508B1
  申请人：——

  公开号：US6479508B1

  公开（公告）日：2002-11-12
• US6794404B2
  申请人：——

  公开号：US6794404B2

  公开（公告）日：2004-09-21
• US7439258B2
  申请人：——

  公开号：US7439258B2

  公开（公告）日：2008-10-21
• 2-Mercaptoimidazoles, a new class of potent CCR2 antagonists
  作者：Guy Van Lommen、Julien Doyon、Erwin Coesemans、Staf Boeckx、Marina Cools、Mieke Buntinx、Bart Hermans、Jean VanWauwe

  DOI：10.1016/j.bmcl.2004.11.064

  日期：2005.2

  We describe the synthesis and SAR of a new class of CCR2 antagonists based on a 2-mercaptoimidazole scaffold. The initial lead 1a was optimized to the 3,4-disubstituted analogues 1p-(S) and 1q-(S), which have IC50 values in the MCP-1 induced Ca-flux below 0.01 muM. (C) 2004 Elsevier Ltd. All rights reserved.